Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Frustrated Boehringer breaks off German Trajenta price talks

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim is breaking off price negotiations for its DPP-4 inhibitor Trajenta (linagliptin) with the GKV, the German association of sickness funds, the firm has told Scrip. The move comes as the company's frustration mounts with the new early benefit assessments that all new drugs must undergo in Germany.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC017168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel